Parnaparin sodium
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| (verify) | |
Parnaparin is an antithrombotic and belongs to the group of low molecular weight heparins. In the prevention and therapy of thromboembolic pathologies, the advent of this class of drugs represented a medical development, since they retain the same effectiveness of unfractionated heparin but with simpler dosing regimens and decreased side effects. In addition to being effective in treating proven deep vein thrombosis and thrombosis-associated phlebopathies, Parnaparin has demonstrated its thromboprophylactic efficacy in both high- and moderate-risk surgical patients.
External links
- parnaparin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Maugeri N, Di Fabio G, Barbanti M, de Gaetano G, Donati MB, Cerletti C (2007). "Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood". Thromb. Haemost. 97 (6): 965–73. doi:10.1160/th06-12-0680. PMID 17549299.
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |